Abstract Details

Title Treatment of High Blood Pressure is associated with a Reduced Incidence of Parkinson’s disease

Presentations S42 - Movement Disorders: Genetics and Risk Modifiers

Background Several drugs including treatments for cardiovascular diseases have been associated with a reduced incidence of PD.

Objective We performed an agnostic drug-wide association study (DWAS) in Norway estimating the association between all drugs prescribed in Norway and the subsequent incidence of Parkinson's disease (PD).

Design/Methods We employed data on drug use in the entire Norwegian population from 2004 to 2019 (4.6 million) registered in the Norwegian Prescription Registry, including more than 600 million individual prescriptions. Drug classes were screened according to ATC codes at level 2, corresponding to therapeutic subgroups. Individuals who developed PD during the 15 years of follow-up (n=15,849) were identified using an algorithm based on drugs prescribed to treat the disease. Cox regression models with exposure as time-dependent variable were specified, and all p-values were corrected for multiple testing using the false discovery rate.

Results We found several novel associations between drug classes and the incidence of PD including a decreased incidence of PD among users of drugs acting on the renin-angiotensin system (0.86, 95%CI: 0.83-0.89). We also found an inverse association between calcium channel blockers and PD incidence, but we could not confirm the previously reported association between lipid-modifying agents and PD. Further, beta blocking agents and drugs for cardiac therapy were associated with an increased PD incidence. We also found increased PD incidence for drugs used in the treatment of prodromal symptoms of PD, including urologicals, drugs for constipation, anti-psychotics, and antidepressants.

Conclusions We observed two large drug classes of anti-hypertensives being associated with a subsequent reduced incidence of PD. The finding of two other cardiovascular drug classes being associated with an increased PD incidence calls for more detailed epidemiological studies and experimental studies to elucidate possible mechanisms.

Authors/Disclosures
Trond Riise PRESENTER	Trond Riise has nothing to disclose.
Clemens R. Scherzer, MD (Brigham and Women'S Hospital/Harvard Medical School)	Dr. Scherzer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Scherzer has received research support from NIH. The institution of Dr. Scherzer has received research support from Michael J. Fox Foundation. The institution of Dr. Scherzer has received research support from American Parkinson's Disease Association. Dr. Scherzer has received intellectual property interests from a discovery or technology relating to health care.
Marianna Cortese, MD, PhD (Harvard T.H. Chan School of Public Health)	Dr. Cortese has received personal compensation in the range of $500-$4,999 for serving as a speaker at educational event with Roche.
Kjetil Bjornevik, MD, PhD (Harvard T.H. Chan School of Public Health)	The institution of Dr. Bjornevik has received research support from Michael J. Fox Foundation. The institution of Dr. Bjornevik has received research support from National Multiple Sclerosis Society. The institution of Dr. Bjornevik has received research support from Department of Defense.
Julia Axiina Tuominen, MPsych	Miss Tuominen has nothing to disclose.
Magne Solheim, Other	Mr. Solheim has nothing to disclose.
Julia Romanowska, PhD (Universitetet i Bergen)	Mrs. Romanowska has nothing to disclose.
Jannicke Igland, PhD (University of Bergen)	Dr. Igland has nothing to disclose.
Asieh Abolpour Mofrad, PhD (University of Bergen, Department of Global Public Health and Primary Care)	Dr. Abolpour Mofrad has nothing to disclose.